Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C41H67NO15 |
Molecular Weight | 813.9684 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 16 / 16 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(C[C@@](C)(O)[C@@H](OC(=O)CC)[C@H](C)O1)O[C@@H]2[C@@H](C)O[C@@]([H])(O[C@H]3[C@@H](CC=O)C[C@@H](C)[C@@H](O)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@H](OC(=O)CC)[C@@H]3OC)[C@H](O)[C@H]2N(C)C
InChI
InChIKey=DMUAPQTXSSNEDD-QALJCMCCSA-N
InChI=1S/C41H67NO15/c1-11-30(45)54-29-21-32(47)51-24(4)16-14-13-15-17-28(44)23(3)20-27(18-19-43)37(38(29)50-10)57-40-35(48)34(42(8)9)36(25(5)53-40)56-33-22-41(7,49)39(26(6)52-33)55-31(46)12-2/h13-15,17,19,23-29,33-40,44,48-49H,11-12,16,18,20-22H2,1-10H3/b14-13+,17-15+/t23-,24-,25-,26+,27+,28+,29-,33+,34-,35-,36-,37+,38+,39+,40+,41-/m1/s1
Molecular Formula | C41H67NO15 |
Molecular Weight | 813.9684 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 16 / 16 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://en.remedy-info.com/makropen.htmlCurator's Comment: Description was created based on several sources, including http://www.antibiotic.ru/cmac/pdf/9_1_066.pdf
Sources: http://en.remedy-info.com/makropen.html
Curator's Comment: Description was created based on several sources, including http://www.antibiotic.ru/cmac/pdf/9_1_066.pdf
Midecamycin (Acetate) is a macrolide antibiotic with actions and uses similar to those of erythromycin but somewhat less active. It is synthesized from Streptomyces mycarofaciens. It has been given by mouth to treat variety of bacterial infections like respiratory tract, ear, skin infections etc. Antibiotics require constant drug level in body for therapeutic effect. This is achieved by taking the drug at regular interval of time throughout the day and night as prescribed. Midecamycin (Acetate) is primarily indicated in conditions like Bronchitis, Laryngopharyngitis, Otitis media, Periodontitis, Pneumonia, Respiratory tract infections, Skin infections, Subcutaneous abscess, Tonsillitis. Midecamycin inhibits bacterial growth by targeting the 50S ribosomal subunit preventing peptide bond formation and translocation during protein synthesis. Resistance to midecamycin is commonly attributed to mutations in 50S rRNA preventing midecamycin binding allowing the cell to synthesize proteins free of error.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: map03010 Sources: http://www.kegg.jp/entry/D01339 |
|||
Target ID: Streptococcus pneumoniae growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/8389685 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Macropen Approved UseMacropen used to treat infectious and inflammatory diseases caused by susceptible microorganisms midecamycin:
Infections of the genitourinary system caused by Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum, and Legionella spp.;
Respiratory tract infections (including those caused by atypical pathogens Chlamydia spp, Mycoplasma spp, Ureaplasma urealyticum, and Legionella spp..): sinusitis, acute otitis media, community-acquired pneumonia, tonzillofaringit, exacerbation of chronic bronchitis;
Infections of the skin and subcutaneous tissue;
Enteritis caused by Campylobacter spp.
Furthermore, the drug is used for treatment and prevention of pertussis and diphtheria. |
|||
Curative | Macropen Approved UseMacropen used to treat infectious and inflammatory diseases caused by susceptible microorganisms midecamycin:
Infections of the genitourinary system caused by Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum, and Legionella spp.;
Respiratory tract infections (including those caused by atypical pathogens Chlamydia spp, Mycoplasma spp, Ureaplasma urealyticum, and Legionella spp..): sinusitis, acute otitis media, community-acquired pneumonia, tonzillofaringit, exacerbation of chronic bronchitis;
Infections of the skin and subcutaneous tissue;
Enteritis caused by Campylobacter spp.
Furthermore, the drug is used for treatment and prevention of pertussis and diphtheria. |
|||
Curative | Midecamycin Meiji Approved UseResp tract, skin & soft tissue infections, UTI. Launch Date1972 |
|||
Curative | Midecamycin Meiji Approved UseResp tract, skin & soft tissue infections, UTI. Launch Date1972 |
Sample Use Guides
Adult 800-1200 mg. Children 600 mg daily. To be taken daily in 3-4 divided doses.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9852316
Midecamycin (10 uM) reduced Ca2+ uptake by rabbit terminal cisternae vesicles to approximately 76% without Ruthenium Red and to approximately 90 % with Ruthenium Red.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:56:49 GMT 2023
by
admin
on
Fri Dec 15 18:56:49 GMT 2023
|
Record UNII |
N34Z0Y5UH7
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
J01FA03
Created by
admin on Fri Dec 15 18:56:49 GMT 2023 , Edited by admin on Fri Dec 15 18:56:49 GMT 2023
|
||
|
WHO-VATC |
QJ01FA03
Created by
admin on Fri Dec 15 18:56:49 GMT 2023 , Edited by admin on Fri Dec 15 18:56:49 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5282169
Created by
admin on Fri Dec 15 18:56:49 GMT 2023 , Edited by admin on Fri Dec 15 18:56:49 GMT 2023
|
PRIMARY | |||
|
1861
Created by
admin on Fri Dec 15 18:56:49 GMT 2023 , Edited by admin on Fri Dec 15 18:56:49 GMT 2023
|
PRIMARY | |||
|
MIDECAMYCIN
Created by
admin on Fri Dec 15 18:56:49 GMT 2023 , Edited by admin on Fri Dec 15 18:56:49 GMT 2023
|
PRIMARY | |||
|
m7532
Created by
admin on Fri Dec 15 18:56:49 GMT 2023 , Edited by admin on Fri Dec 15 18:56:49 GMT 2023
|
PRIMARY | Merck Index | ||
|
DB13456
Created by
admin on Fri Dec 15 18:56:49 GMT 2023 , Edited by admin on Fri Dec 15 18:56:49 GMT 2023
|
PRIMARY | |||
|
100000080607
Created by
admin on Fri Dec 15 18:56:49 GMT 2023 , Edited by admin on Fri Dec 15 18:56:49 GMT 2023
|
PRIMARY | |||
|
3461
Created by
admin on Fri Dec 15 18:56:49 GMT 2023 , Edited by admin on Fri Dec 15 18:56:49 GMT 2023
|
PRIMARY | |||
|
154011
Created by
admin on Fri Dec 15 18:56:49 GMT 2023 , Edited by admin on Fri Dec 15 18:56:49 GMT 2023
|
PRIMARY | |||
|
30005
Created by
admin on Fri Dec 15 18:56:49 GMT 2023 , Edited by admin on Fri Dec 15 18:56:49 GMT 2023
|
PRIMARY | RxNorm | ||
|
C174736
Created by
admin on Fri Dec 15 18:56:49 GMT 2023 , Edited by admin on Fri Dec 15 18:56:49 GMT 2023
|
PRIMARY | |||
|
C026483
Created by
admin on Fri Dec 15 18:56:49 GMT 2023 , Edited by admin on Fri Dec 15 18:56:49 GMT 2023
|
PRIMARY | |||
|
CHEMBL1908336
Created by
admin on Fri Dec 15 18:56:49 GMT 2023 , Edited by admin on Fri Dec 15 18:56:49 GMT 2023
|
PRIMARY | |||
|
N34Z0Y5UH7
Created by
admin on Fri Dec 15 18:56:49 GMT 2023 , Edited by admin on Fri Dec 15 18:56:49 GMT 2023
|
PRIMARY | |||
|
252-578-0
Created by
admin on Fri Dec 15 18:56:49 GMT 2023 , Edited by admin on Fri Dec 15 18:56:49 GMT 2023
|
PRIMARY | |||
|
SUB08951MIG
Created by
admin on Fri Dec 15 18:56:49 GMT 2023 , Edited by admin on Fri Dec 15 18:56:49 GMT 2023
|
PRIMARY | |||
|
35457-80-8
Created by
admin on Fri Dec 15 18:56:49 GMT 2023 , Edited by admin on Fri Dec 15 18:56:49 GMT 2023
|
PRIMARY | |||
|
DTXSID5045463
Created by
admin on Fri Dec 15 18:56:49 GMT 2023 , Edited by admin on Fri Dec 15 18:56:49 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |